InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

Current share price for ACL : $2.920 0.04 (1.39%)+

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$545 Fondaparinux Quarterly Profit Share 27 Nov 2014 11:12AM $0.088 $2.920 risen by 3,218.18%
$545 Departure of Chief Executive Officer 11 Nov 2014 8:29AM $0.095 $2.920 risen by 2,973.68%
$545 Phase III Trial Results for HA-Irinotecan 27 Oct 2014 8:31AM $0.620 $2.920 risen by 370.97%
$545 Appendix 4C - quarterly 17 Oct 2014 8:38AM $0.640 $2.920 risen by 356.25%
$545 Database Lock for HA-Irinotecan Pivotal Phase III Trial 10 Oct 2014 10:26AM $0.670 $2.920 risen by 335.82%
$545 Update on Phase III Trial of HA-Irinotecan in mCRC 12 Sep 2014 10:22AM $0.620 $2.920 risen by 370.97%
$545 Preliminary Final Report and Financial Statements 29 Aug 2014 2:50PM $0.605 $2.920 risen by 382.64%
$545 Fondaparinux Quarterly Profit Share 28 Aug 2014 4:27PM $0.620 $2.920 risen by 370.97%
$545 Appendix 4C - quarterly 29 Jul 2014 8:28AM $0.570 $2.920 risen by 412.28%
$545 CHIME Trial First Patient Enrolled 19 Jun 2014 2:22PM $0.495 $2.920 risen by 489.90%
$545 HA-Irinotecan Phase III Trial Timeline Update 5 Jun 2014 12:14PM $0.510 $2.920 risen by 472.55%
$545 Fondaparinux Quarterly Profit Share 30 May 2014 4:21PM $0.480 $2.920 risen by 508.33%
$545 Appendix 4C - quarterly 28 Apr 2014 8:27AM $0.540 $2.920 risen by 440.74%
$545 Alchemia Licenses novel FAK Inhibitors from CRT 5 Mar 2014 1:00PM $0.570 $2.920 risen by 412.28%
$545 Appointment of Thomas Liquard as CEO 24 Feb 2014 9:45AM $0.615 $2.920 risen by 374.80%
$545 Fondaparinux Quarterly Profit Share 17 Feb 2014 5:20PM $0.600 $2.920 risen by 386.67%
$545 Half Yearly Report and Accounts 17 Feb 2014 5:16PM $0.600 $2.920 risen by 386.67%
$545 Appendix 4C - quarterly 24 Jan 2014 8:28AM $0.570 $2.920 risen by 412.28%
$545 HA-Irinotecan and Fondaparinux Profit Share Update 28 Nov 2013 8:27AM $0.595 $2.920 risen by 390.76%
$545 Fondaparinux Update 1 Nov 2013 11:10AM $0.580 $2.920 risen by 403.45%
$545 R&D Tax Incentive and Investigator-sponsored Phase II Small 29 Oct 2013 9:58AM $0.600 $2.920 risen by 386.67%
$545 Appendix 4C - quarterly 29 Oct 2013 8:49AM $0.600 $2.920 risen by 386.67%
$545 Preliminary Final Report and Financial Statements 30 Aug 2013 2:11PM $0.415 $2.920 risen by 603.61%
$545 Record Fondaparinux Quarterly Profit Share 20 Aug 2013 8:25AM $0.415 $2.920 risen by 603.61%
$545 Appendix 4C - quarterly 30 Jul 2013 9:35AM $0.355 $2.920 risen by 722.54%

826 - 850 of 1019 results

Page 34 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.